研究業績

学術論文

 

 

  • Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studiesD Novitasari, I Nakamae, RI Jenie, N Yoneda-Kato, J Kato, E MeiyantoSaudi Pharmaceutical Journal 32 (1), 101892, 2024
  • Tumour‐suppressive effects of curcumin analogs CCA‐1.1 and pentagamavunone‐1 in colon cancer: in vivo and in vitro studiesF Wulandari, M Ikawati, S Widyarini, M Kirihata, D Novitasari, J Kato, ...Journal of advanced pharmaceutical technology & research 14 (4), 317-324, 2023
  • PGV-1 permanently arrests HepG2 cells in M phase and inhibits liver carcinogenesis in DMH-induced ratsD Novitasari, J Kato, DDP Putri, F Wulandari, S Widyarini, UM Zulfin, ...Journal of Applied Pharmaceutical Science 13 (8), 204-211, 2023
  • Chemoprevention curcumin analog 1.1 promotes metaphase arrest and enhances intracellular reactive oxygen species levels on TNBC MDA-MB-231 and HER2-positive HCC1954 cells. D Novitasari, RI Jenie, J Kato, E MeiyantoResearch in Pharmaceutical Sciences 18 (4), 358-370 6 2023
  • Curcumin analogs PGV-1 and CCA-1.1 induce cell cycle arrest in human hepatocellular carcinoma cells with overexpressed MYCNM Moordiani, D Novitasari, RA Susidarti, J Kato, E MeiyantoThe Indonesian Biomedical Journal 15 (2), 141-9 3 2023
  • Network pharmacological analysis identifies the curcumin analog CCA-1.1 targeting mitosis regulatory process in HER2-positive breast cancerD Novitasari, RI Jenie, J Kato, E MeiyantoIndonesian Journal of Pharmacy 2 2023
  • Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft modelsN Kamitani, I Nakamae, N Yoneda-Kato, J Kato, M ShoScientific Reports 12 (1), 22419 2 2022
  • Antimigratory evaluation from curcumin-derived synthetic compounds PGV-1 and CCA-1.1 on HCC1954 and MDA-MB-231 cells D Novitasari, E Meiyanto, J Kato, RI JenieIndonesian Journal of Cancer Chemoprevention 13 (2), 71-82 4 2022
  • Preparation and cytotoxic evaluation of PGV-1 derivative, CCA-1.1, as a new curcumin analog with improved-physicochemical and pharmacological properties RY Utomo, F Wulandari, D Novitasari, B Lestari, RA Susidarti, RI Jenie, ...Advanced Pharmaceutical Bulletin 12 (3), 603, 2022
  • CCA-1.1 exerts cytotoxic activities against TNBC and HER2-enriched breast cancer: in vitro and bioinformatic studiesN Dhania, F Wulandari, RY Utomo, RI Jenie, J Kato, E MeiyantoCANCER SCIENCE 113, 1030-1030 2022
  • Targeting Abnormal Cell Cycle in Cancer: A Preface to the Special IssueC Takahashi, J KatoOnco 2 (1), 34-35, 2022
  • Bioinformatic and molecular interaction studies uncover that CCA-1.1 and PGV-1 differentially target mitotic regulatory protein and have a synergistic effect against leukemia cellsE Meiyanto, D Novitasari, RY Utomo, RA Susidarti, DDP Putri, J Kato Indonesian Journal of Pharmacy, 225–233-225–233, 2022
  • The integrative bioinformatic analysis deciphers the predicted molecular target gene and pathway from curcumin derivative CCA-1.1 against triple-negative breast cancer (TNBC) D Novitasari, RI Jenie, J Kato, E Meiyanto Journal of the Egyptian National Cancer Institute 33, 1-10, 2021
  • A new curcumin analog, CCA-1.1, induces cell death and cell cycle arrest in WiDr colon cancer cells via ROS generation F Wulandari, M Ikawati, M Kirihata, JY Kato, E Meiyanto Journal of Applied Pharmaceutical Science 11 (10), 099-105, 2021
  • The Two Mono-Carbonyl Curcumin Analogs, PGV-1 and CCA-1.1: The Chemopreventive Activity Against DMH-Induced Colorectal Cancer Rat and Proteins Target Candidate Involved F Wulandari, M Kirihata, S Widyarini, JY Kato, E Meiyanto 2021
  • Curcumin analogs, PGV-1 and CCA-1.1 exhibit anti-migratory effects and suppress MMP9 expression on WiDr cells F Wulandari, M Kirihata, JY Kato, E Meiyanto The Indonesian Biomedical Journal 13 (3), 271-80, 2021
  • Stabilization of fatty acid synthesis enzyme acetyl-CoA carboxylase 1 suppresses acute myeloid leukemia developmentH Ito, I Nakamae, J Kato, N Yoneda-Kato The Journal of clinical investigation 131 (12), 2021
  • CCA-1.1, a novel curcumin analog, exerts cytotoxic anti-migratory activity toward TNBC and HER2-enriched breast cancer cellsD Novitasari, RI Jenie, RY Utomo, J Kato, E Meiyanto Asian Pacific Journal of Cancer Prevention: APJCP 22 (6), 1827, 2021
  • Evaluation of Cytotoxic Activity of Curcumin Like Structure (CCA-1.1) Against Metastatic Breast Cancer Cells D Novitasari, RI Jenie, DDD Putri, F Wulandari, J Kato, E Meiyanto CANCER SCIENCE 112, 934-934 2021
  • Synthetic Inhibitors of CDK4/6 Activities and Tumor Suppression: A Preface to the Special IssueC Takahashi, J Kato Onco 1 (1), 1-2 2021
  • The anti-migratory activity of a new curcumin analog, CCA-1.1, against T47D breast cancer cells. F WULANDARI, RY UTOMO, D NOVITASARI, M IKAWATI, M KIRIHATA, ...International Journal of Pharmaceutical Research (09752366) 13 (1), 2021
  • A new curcumin analog, CCA-1.1, induces cell cycle arrest and senescence toward ER-positive breast cancer cells. D NOVITASARI, F WULANDARI, RI JENIE, RY UTOMO, JUNYA KATO, ...International Journal of Pharmaceutical Research (09752366) 13 (1), 2021
  • The target differences of anti-tumorigenesis potential of curcumin and its analogues against HER-2 positive and triple-negative breast cancer cells E Meiyanto, U Husnaa, RF Kastian, H Putri, YA Larasati, A Khumaira, ...Advanced Pharmaceutical Bulletin 11 (1), 188, 2021
  • Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1 D Novitasari, RI Jenie, F Wulandari, RY Utomo, DDP Putri, J Kato, ...Research Journal of Pharmacy and Technology 14 (8), 4375-4382, 2021
  • New curcumin analog, CCA-1.1, synergistically improves the antiproliferative effect of doxorubicin against T47D breast cancer cells F Wulandari, D Novitasari, M Kirihata, J Kato, E Meiyanto Indonesian Journal of Pharmacy, 244-256, 2020
  • Curcumin derivatives verify the essentiality of ROS upregulation in tumor suppression I Nakamae, T Morimoto, H Shima, M Shionyu, H Fujiki, N Yoneda-Kato, ... Molecules 24 (22), 4067 45 2019
  • Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence B Lestari, I Nakamae, N Yoneda-Kato, T Morimoto, S Kanaya, ...Scientific Reports 9 (1), 14867 44 2019
  • Anti-proliferative and anti-metastatic potential of curcumin analogue, pentagamavunon-1 (PGV-1), toward highly metastatic breast cancer cells in correlation with ROS generation. E Meiyanto, H Putri, YA Larasati, RY Utomo, RI Jenie, M Ikawati, B Lestari, ... Advanced pharmaceutical bulletin 9 (3), 445 54 2019
  • Cell cycle modulation of CHO-K1 cells under genistein treatment correlates with cells senescence, apoptosis and ROS level but in a dose-dependent manner RI Jenie, ND Amalina, GPN Ilmawati, RY Utomo, M Ikawati, A Khumaira, ... Advanced Pharmaceutical Bulletin 9 (3), 453 31 2019
  • Tumor suppression by controlling intercellular levels of ROS through ROS metabolic enzymes by curcumin derivatives I Nakamae, N Kato, T Yokoyama, E Meiyanto, J Kato CANCER SCIENCE 109, 932-932 2018
  • COP1-Trib1 targets ACC1 for degradation and protects leukemic cells from metabolic stress in acute myeloid leukemia. H Ito, I Nakamae, T Yokoyama, J Kato, N Kato CANCER SCIENCE 109, 250-250 2018
  • Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. YA Larasati, N Yoneda-Kato, I Nakamae, T Yokoyama, E Meiyanto, J Kato. Scientific reports 8 (1), 2039 196 2018
  • Curcumin targets multiple enzymes functioning in the ROS metabolic pathway to suppress tumor cell growth.. J Kato, Y Larasati, I Nakamae, T Yokoyamal, E Meiyanto, N Kato CANCER SCIENCE 109, 234-234 2018
  • Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBPα to prevent Trib1-driven acute myeloid leukemia I Nakamae, J Kato, T Yokoyama, H Ito, N Yoneda-Kato Blood advances 1 (20), 1682-1693 17 2017
  • Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs. Y Kukita, J Okami, N Yoneda-Kato, I Nakamae, T Kawabata, ... Molecular Case Studies 2 (6), a001032 20 2016
  • Cytoplasmic retention of CDC6 induces premature senescence in immortalized cells and suppresses tumor formation in mice. A Ueda, N Yoneda-Kato, Y Yamanaka, I Nakamae, J Kato. Journal of Hematology and Oncology Research 2 (2), 27-42 1 2016
  • The COP1 E3-ligase interacts with FIP200, a key regulator of mammalian autophagy. S Kobayashi, N Yoneda-Kato, N Itahara, A Yoshida, J Kato. BMC biochemistry 14, 1-8 11 2013
  • COP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1. A Yoshida, J Kato, I Nakamae, N Yoneda-Kato. Blood, The Journal of the American Society of Hematology 122 (10), 1750-1760 91 2013.
  • CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner. A Yoshida, N Yoneda-Kato, J Kato. Scientific reports 3 (1), 1054 58 2013
  • Depletion of CSN5 inhibits Ras-mediated tumorigenesis by inducing premature senescence in p53-null cells. I Tsujimoto, A Yoshida, N Yoneda-Kato, J Kato. FEBS letters 586 (24), 4326-4331 11 2012
  • New twist in the regulation of cyclin D1. J Kato, N Yoneda-Kato. Walter de Gruyter 1 (5-6), 403-409 5 2010
  • CSN5/Jab1 controls multiple events in the mammalian cell cycle. A Yoshida, N Yoneda-Kato, M Panattoni, R Pardi, J Kato. FEBS letters 584 (22), 4545-4552 36 2010
  • Mammalian COP9 signalosome. J Kato, N Yoneda‐Kato. Genes to Cells 14 (11), 1209-1225 188 2009
  • Overexpression of adenovirus-mediated p27kip1 lacking the Jab1-binding region enhances cytotoxicity and inhibits xenografted human cholangiocarcinoma growth. S Shiraso, Y Katayose, K Yamamoto, M Mizuma, S Yabuuchi, A Oda, ... Anticancer Research 29 (6), 2015-2024 17 2009
  • Isolation and characterization of cytoplasmic cyclin D1 mutants. H Murakami, M Horihata, S Andojo, N Yoneda-Kato, J Kato. FEBS letters 583 (10), 1575-1580 6 2009
  • Stable Form of JAB1 Enhances Proliferation and Maintenance of Hematopoietic Progenitors. M Mori, N Yoneda-Kato, A Yoshida, J Kato. Journal of Biological Chemistry 283 (43), 29011-29021 43 2008
  • Small mitochondrial ARF (smARF) is located in both the nucleus and cytoplasm, induces cell death, and activates p53 in mouse fibroblasts. Y Ueda, T Koya, N Yoneda-Kato, J Kato. FEBS letters 582 (10), 1459-1464 16 2008
  • The myeloid leukemia factor interacts with COP9 signalosome subunit 3 in Drosophila melanogaster. W Sugano, K Ohno, N Yoneda‐Kato, J Kato, M Yamaguchi. The FEBS journal 275 (3), 588-600 8 2008
  • Shuttling imbalance of MLF1 results in p53 instability and increases susceptibility to oncogenic transformation. N Yoneda-Kato, J Kato. Molecular and cellular biology 28 (1), 422-434 47 2008
  • Signal‐Response Coupling Mediated by the Transduced Colony‐Stimulating Factor‐1 Receptor and its Oncogenic fms Variants in Naive Cells. CJ Sherr, J Kato, G Borzillo, JR Downing, MF Roussel. Ciba Foundation Symposium 148‐Molecular Control of Haemopoiesis: Molecular … 7 2007
  • MAbs against mammalian Jab1/CSN5 protein. JY Kato. HYBRIDOMA 25 (6), 387-387 2006
  • Preparation and characterization of monoclonal antibodies against mouse Jab1/CSN5 protein. JY Kato, I Nakamae, K Tomoda, A Fukumoto, N Yoneda-Kato. Hybridoma and Hybridomics 25 (6), 342-348 10 2006
  • Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines. A Fukumoto, K Tomoda, N Yoneda-Kato, Y Nakajima, J Kato. FEBS letters 580 (25), 5836-5844 44 2006
  • Myeloid leukemia factor 1 regulates p53 by suppressing COP1 via COP9 signalosome subunit 3. N Yoneda‐Kato, K Tomoda, M Umehara, Y Arata, J Kato. The EMBO journal 24 (9), 1739-1749 122 2005
  • Small Jab1-containing subcomplex is regulated in an anchorage-and cell cycle-dependent manner, which is abrogated by ras transformation. A Fukumoto, K Tomoda, M Kubota, J Kato, N Yoneda-Kato. FEBS letters 579 (5), 1047-1054 66 2005
  • The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression. K Tomoda, J Kato, E Tatsumi, T Takahashi, Y Matsuo, N Yoneda-Kato. Blood 105 (2), 775-783 94 2005
  • Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. K Tomoda, N Yoneda-Kato, A Fukumoto, S Yamanaka, J Kato. Journal of Biological Chemistry 279 (41), 43013-43018 202 2004.
  • Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. A Goto, T Niki, S Moriyama, N Funata, H Moriyama, Y Nishimura, ... Pathology international 54 (9), 675-681 77 2004
  • Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. A Fukumoto, N Ikeda, M Sho, K Tomoda, H Kanehiro, M Hisanaga, .... Oncology reports 11 (2), 277-284 90 2004
  • Regulatuion of Cdk inhibitor p27Kip1. K Tomoda, N Kato, JY Kato. JOURNAL OF PHARMACOLOGICAL SCIENCES 94, 26P-26P 2004
  • Dominant negative E2F inhibits progression of the cell cycle after the midblastula transition in Xenopus. T Tanaka, T Ono, N Kitamura, J Kato. Cell structure and function 28 (6), 515-522 7 2003
  • In vivo analysis of the cyclin D1 promoter during early embryogenesis in Xenopus. T Tanaka, M Kubota, K Shinohara, K Yasuda, J Kato. Cell structure and function 28 (3), 165-177 19 2003
  • Expression of Cyclin‐dependent Kinase Inhibitor p27/Kipl and AP‐1 Coactivator p38/Jabl Correlates with Differentiation of Embryonal Rhabdomyosarcoma. R Tsuchida, J Miyauchi, L Shen, M Takagi, Y Tsunematsu, M Saeki, ... Japanese Journal of Cancer Research 93 (9), 1000-1006 23 2002
  • The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. K Tomoda, Y Kubota, Y Arata, S Mori, M Maeda, T Tanaka, M Yoshida, ... Journal of Biological Chemistry 277 (3), 2302-2310 392 2002
  • CDK Inhibitors J Kato, K Tomoda, Y Arata, T Tanaka, N Yoneda-Kato. Tumor Suppressing Viruses, Genes, and Drugs, 123-143 2002
  • PROTEIN SYNTHESIS, POST-TRANSLATION MODIFICATION, AND DEGRADATION-The cytoplasmic shuttling and subsequent degradation of p27kipl mediated by Jab1/CSN5 and the COP9 signalosome … K Tomoda, Y Kubota, Y Arata, S Mori, M Maeda, T Tanaka, M Yoshida, ... Journal of Biological Chemistry 277 (3), 2302-2310 2002
  • CDK inhibitors: genes and drugs. J Kato, K Tomoda, Y Arata, T Tanaka, N Yoneda-Kato. Tumor Suppressing Virus, Genes, and Drugs: Innovative Cancer Therapy … 4 2001.
  • Pex19p dampens the p19ARF-p53-p21WAF1 tumor suppressor pathway. T Sugihara, SC Kaul, J Kato, RR Reddel, H Nomura, R Wadhwa. Journal of Biological Chemistry 276 (22), 18649-18652 62 2001.
  • Direct binding of the signal-transducing adaptor Grb2 facilitates down-regulation of the cyclin-dependent kinase inhibitor p27Kip1. Y Sugiyama, K Tomoda, T Tanaka, Y Arata, N Yoneda-Kato, J Kato. Journal of Biological Chemistry 276 (15), 12084-12090 51 2001
  • PROTEIN SYNTHESIS, POST-TRANSLATION MODIFICATION, AND DEGRADATION-Direct binding of the signal-transducing adaptor Grb2 facilitates down-regulation of the cyclin-dependent …. Y Sugiyama, K Tomoda, T Tanaka, Y Arata, N Yoneda-Kato, J Kato. Journal of Biological Chemistry 276 (15), 12084-12090 2001
  • Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma. L Shen, R Tsuchida, J Miyauchi, M Saeki, T Honna, Y Tsunematsu, J Kato, ... International journal of oncology 17 (4), 749-803 34 2000.
  • Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. XW Deng, W Dubiel, N Wei, K Hofmann, K Mundt, J Colicelli, J Kato, ... Trends in Genetics 16 (5), 202-203 236 2000.
  • Cdk2-dependent and-independent pathways in E2F-mediated S phase induction. Y Arata, M Fujita, K Ohtani, S Kijima, J Kato. Journal of Biological Chemistry 275 (9), 6337-6345 115 2000.
  • Induction of S phase by G1 regulatory factors. J Kato. Front Biosci 4 (4), D787-D792 86 1999
  • NPM-MLF1 fusion protein downregulates p27 (kip1) through the novel Jab1-mediated pathway. N Yoneda-Kato, JY Kato. Blood 94 (10), 484A-484A 5 1999
  • Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein. N Yoneda-Kato, S Fukuhara, J Kato. Oncogene 18 (25), 3716-3724 41 1999.
  • p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts. K Kurokawa, T Tanaka, J Kato. Oncogene 18 (17), 2718-2727 49 1999
  • Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. K Tomoda, Y Kubota, J Kato. Nature 398 (6723), 160-165 797 1999
  • Eight calves cloned from somatic cells of a single adult. Y Kato, T Tani, Y Sotomaru, K Kurokawa, J Kato, H Doguchi, H Yasue, ... Science 282 (5396), 2095-2098 1503 1998
  • Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein. N Yoneda-Kato, N Matsumoto, S Fukuhara, JY Kato. BLOOD 92 (10), 419A-419A 1998
  • Transcription factor E2F and cyclin E-Cdk2 complex cooperate to induce chromosomal DNA replication in Xenopus oocytes. E Akamatsu, T Tanaka, J Kato. Journal of Biological Chemistry 273 (26), 16494-16500 28 1998.
  • Cyclic AMP delays G2 progression and prevents efficient accumulation of cyclin B1 proteins in mouse macrophage cells. K Kurokawa, J Kato. Cell structure and function 23 (6), 357-365 18 1998.
  • Cdk inhibiting proteins. K Tomoda, J Kato. Gan to Kagaku ryoho. Cancer & Chemotherapy 24 (11), 1407-1413 3 1997
  • Control of G1 progression by D-type cyclins: key event for cell proliferation. J Kato Leukemia (08876924) 11 28 1997
  • The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2. M Kitagawa, H Higashi, HK Jung, I Suzuki‐Takahashi, M Ikeda, K Tamai, ... The EMBO journal 15 (24), 7060-7069 705 1996
  • E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF. T Yoshihara, T Inaba, LH Shapiro, JY Kato, AT Look. Molecular and cellular biology 73 1995
  • Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. H Hirai, MF Roussel, JY Kato, RA Ashmun, CJ Sherr. Molecular and cellular biology 939 1995.
  • Positive and Negative Regulation of D-Type Cyclin-Dependent Kinases during G1 Progression. CJ Sherr, M Matsuoka, J Kato, MF Roussel, DE Quelle. Journal of Cellular Biochemistry, 6-6 1 1995
  • Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. J Kato, M Matsuoka, K Polyak, J Massague, CJ Sherr. Cell 79 (3), 487-496 992 1994
  • Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. M Matsuoka, JY Kato, RP Fisher, DO Morgan, CJ Sherr. Molecular and cellular biology 14 (11), 7265-7275 285 1994
  • Inhibition of cyclin‐dependent kinases by purine analogues. J Veselý, L Havliček, M Strnad, JJ Blow, A Donella‐Deana, L Pinna, ... European journal of biochemistry 224 (2), 771-786 807 1994
  • Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. JY Kato, M Matsuoka, DK Strom, CJ Sherr. Molecular and cellular biology 448 1994
  • D-type cyclin-dependent kinase activity in mammalian cells. H Matsushime, DE Quelle, SA Shurtleff, M Shibuya, CJ Sherr, JY Kato. Molecular and cellular biology 14 (3), 2066-2076 1405 1994
  • Monoclonal antibodies to mammalian D-type G1 cyclins. SJ VALLANCE, HMO LEE, MF ROUSSEL, SA SHURTLEFF, ... Hybridoma 13 (1), 37-44 30 1994
  • D-TYPE G1 CYCLINS AS INTEGRATORS OF GROWTH FACTOR-INDUCED SIGNALS. CJ SHERR, JY KATO, MF ROUSSEL, DE QUELLE. JOURNAL OF CELLULAR BIOCHEMISTRY, 6-6 1994.
  • D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. CJ Sherr, J Kato, DE Quelle, M Matsuoka, MF Roussel. Cold spring harbor symposia on quantitative biology 59, 11-19 103 1994
  • p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. K Polyak, JY Kato, MJ Solomon, CJ Sherr, J Massague, JM Roberts, ... Genes & development 8 (1), 9-22 2834 1994
  • Mammalian G1 cyclins in growth control. CJ Sherr, MF Roussel, JY KATO, DE Quelle, M Matsuoka, H Matsushime. Pathologie et biologie 42 (10), 912-913 1994
  • Control of G1 progression by mammalian D-type cyclins. CJ Sherr, H Matsushime, J Kato, DE Quelle, MF Roussel. The Cell Cycle: Regulators, Targets, and Clinical Applications, 17-23 3 1994
  • Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. J Kato, CJ Sherr. Proceedings of the National Academy of Sciences 90 (24), 11513-11517 304 1993
  • Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. DE Quelle, RA Ashmun, SA Shurtleff, JY Kato, D Bar-Sagi, MF Roussel, ... Genes & development 7 (8), 1559-1571 1355 1993
  • Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. ME Ewen, HK Sluss, CJ Sherr, H Matsushime, J Kato, DM Livingston. Cell 73 (3), 487-497 1423 1993
  • Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. JY Kato, H Matsushime, SW Hiebert, ME Ewen, CJ Sherr. Genes & development 7 (3), 331-342 1697 1993
  • GROWTH FACTOR-REGULATED MAMMALIAN G1 (D-TYPE) CYCLINS AND THEIR CYCLIN-DEPENDENT KINASES. CJ SHERR, MF ROUSSEL, D STROM, JY KATO, H MATSUSHIME. JOURNAL OF CELLULAR BIOCHEMISTRY, 222-222 1993
  • CSF-1 regulation of D-type cyclins during the G1 phase of the cell cycle. MF Roussel, H Matsushime, J Kato, CJ Sherr. COLLOQUES-INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE … 1993
  • Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. H Matsushime, ME Ewen, DK Strom, JY Kato, SK Hanks, MF Roussel, ... Cell 71 (2), 323-334 1193 1992
  • Isolation of chicken-bek and a related gene; identification of structural variation in the ligand-binding domains of the FGF-receptor family. M Sato, T Kitazawa, T Iwai, J Seki, N Sakato, J Kato, T Takeya. Oncogene 6 (7), 1279-1283 16 1991
  • A dominant suppressive mutation in a cellular gene restores the nontransformed phenotype to v-fms-transformed mink cells. J Kato, CJ Sherr. Oncogene 6 (5), 687-693 3 1991
  • Regulation of cell growth and differentiation by the colony-stimulating factor 1 receptor. CJ Sherr, GV Borzillo, J Kato, SA Shurtleff, JR Downing, MF Roussel. Seminars in hematology 28 (2), 143-151 9 1991
  • Antibody-Induced Mitogenicity Mediated by a Chimeric CD2–c-fms Receptor. MF Roussel, C Transy, JY Kato, EL Reinherz, CJ Sherr. Molecular and cellular biology 10 (5), 2407-2412 18 1990
  • Human colony-stimulating factor 1 (CSF-1) receptor confers CSF-1 responsiveness to interleukin-3-dependent 32DC13 mouse myeloid cells and abrogates differentiation in response … J Kato, CJ Sherr 35 1990
  • Transduction of human colony-stimulating factor-1 (CSF-1) receptor into interleukin-3-dependent mouse myeloid cells induces both CSF-1-dependent and factor-independent growth. JY Kato, MF Roussel, RA Ashmun, CJ Sherr. Molecular and cellular biology 37 1989
  • Characterization of partially activated p60c-src in chicken embryo fibroblasts. M Sato, J Kato, T Takeya. Journal of virology 63 (2), 683-688 6 1989
  • Substitution of Ser-17 of pp60c-src: Biological and Biochemical Characterization in Chicken Embryo Fibroblasts. Y Hirota, JY Kato, T Takeya. Molecular and cellular biology 8 (4), 1826-1830 20 1988
  • Structural features of the carboxy terminus of p60c-src that are required for the regulation of its intrinsic kinase activity. J KATO, Y HIROTA, N NAKAMURA, N NAKAMURA, T TAKEYA. Japanese Journal of Cancer Research GANN 78 (12), 1354-1362 15 1987
  • Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. JY Kato, T Takeya, C Grandori, H Iba, JB Levy, H Hanafusa. Molecular and cellular biology 213 1986
  • Classification and characterization of oncogene products based on their homology. J Kato, T Takeya. Tanpakushitsu Kakusan koso. Protein, Nucleic Acid, Enzyme, 151-158 1986

Book Chapters and Reviews, 日本語の著書

  • Sherr CJ, Kato J-Y, Borzillo GV, Downing JR, Roussel MF. Signal-response coupling mediated by the transduced colony stimulating factor-1 receptor and its oncogenic fms variants in naive cells. In:Molecular Control of Hematopoiesis, CIBA Symp No 148. London/New York: John Wiley and Sons, Inc, pp96-109, 1990
  • Sherr CJ, Borzillo GV, Kato J-Y, Shurtleff SA, Downing JR, Roussel MF. Regulation of cell growth and differentiation by the colony-stimulating factor 1 receptor (FMS). In: Molecular Regulation of Hematopoiesis. Seminars in Hematology 28:143-151, 1991.
  • Roussel MF, Matsushime H, Kato J-Y, Sherr CJ. CSF-1 regulation of D-type cyclins during the G1 phase of the cell cycle. In: Najman A, Guigon M, Lemoine F, eds. Negative Regulation of Hematopoietic Cell Growth and Differentiation (Vol 229). Montarouge, France: Colloque INSERM/John Libbey Eurotext, Ltd., pp83-89, 1993.
  • Sherr CJ, Quelle DE, Kato J-Y, Shurtleff S, Roussel MF. D-type cyclins and G1 progression. In: Euromedicine 93, 9emes Rencontres Internationales de Recherches et de Technologies Medicales et Pharmaceutiques. Paris: SN Editel, pp223-224, 1993.
  • Sherr CJ, Matsushime H, Kato J-Y, Quelle DE, Roussel MF. Control of G1 progression by mammalian D-type cyclins. In: Hu VW, ed. The Cell Cycle: Regulators, Targets, and Clinical Applications. Plenum Press, New York, pp17-23, 1994.
  • Sherr CJ, Kato J-Y, Quelle DE, Matsuoka M, Roussel MF. D-type cyclins and their cyclin-dependent kinases: G1phase integrators of the mitogenic response. In: Molecular Genetics of Cancer, Cold Spring Hbr Symp Quant Biol LIX June 1-8, 1994.
  • Kato J-Y. Control of G1 progression by D-type cyclins: Key event for cell proliferation. Leukemia 11: 347-351, 1997.
  • Kato J-Y. Induction of S phase by G1 regulatory factors. Frontiers in Bioscience 4: 787-792, 1999
  • Deng XW, Dubiel W, Wei N, Hofmann K, Mundt K, Colicelli J, Kato J-Y, Naumann M, Segal D, Seeger M, Glickman M, Chamovitz DA, Carr A. Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet 16: 202-203, 2000.
  • Kato J-Y, Tomoda K, Arata Y, Tanaka T and Yoneda-Kato N. Cdk inhibitory proteins. In: Maruta H ed. Tumor Suppressing Viruses, Genes and Drugs: Innovative Cancer Therapy Approaches. Academic Press, San Diego, pp123-143, 2001.
  • 加藤順也、竹家達夫　オンコジーンで指令される蛋白質の相同配列 蛋白質・核酸・酵素　２９：１５１ー１５８、１９８６
  • 河原林裕、加藤順也、竹家達夫　癌遺伝子に見られる相同配列　核酸・蛋白質の構造情報（内田久雄編　東京大学出版社）ｐｐ２９ー５４、１９８９
  • 加藤順也　Ｄ型サイクリンによる未分化骨髄細胞株３２Ｄ細胞の顆粒球分化阻害　Medical Immunology 　２８：２０９－２１７、１９９４
  • 加藤順也　Ｇ１サイクリン／ＣｄｋとＣｄｋインヒビターの構造と機能（概論）　実験医学　１３：１５８８ー１５９３、１９９５
  • 加藤順也　細胞周期と発癌　 Molecular Medicine　３２：９４６ー９５１、１９９５
  • 加藤順也　D型サイクリン依存キナーゼの制御とＧ１期進行の分子機構 蛋白質　核酸　酵素　４１：１７１９ー１７２４、１９９６
  • 友田紀一郎、加藤順也　CDK阻害蛋白質　 癌と化学療法　２４：１４０７ー１４１３、１９９７
  • 加藤順也　Ｇ１サイクリンとＣＤＫｓ　 実験医学　１５：１９１１ー１９１６、１９９７
  • 加藤順也　Ｇ１サイクリンの制御機構　 　　 遺伝子医学　１：２７３ー２７４、１９９７
  • 加藤順也　動物の細胞周期制御機構　 BIOClinica　１２：８５８ー８６２、１９９７
  • 加藤順也　ユビキチン化を介したＧ１制御因子の調節 細胞工学　１８：６３２ー６３８、１９９９
  • 加藤順也　HOT PRESS　Jab1によるCDK阻害タンパク質p27Kip1の分解制御 細胞工学　１８： １１７６ー１１７８、１９９９
  • 加藤順也　BioScience用語ライブラリー｢細胞周期　改訂第２版｣ 第２章　動物の細胞周期を制御する基本因子(1)Cdk 2)Cdk2、3)Cdk4/Cdk6、(3)Cdkインヒビター 3)p27
  • 加藤順也　 Cdk阻害蛋白質p27Kip1の制御と細胞の癌化　 Molecular Medicine　３６：１２６４－１２７１ 、１９９９
  • 加藤順也　細胞周期のコントロールと核ｰ細胞質間輸送 実験医学　１７：２４２５－２４３０ 、１９９９
  • 加藤順也　Jab1によるp27Kip1の制御機構 実験医学　１８： ８５２－８５６、２０００
  • 荒田幸信、友田紀一郎、加藤順也　細胞周期制御と発がん 放射線生物研究　３５：　１２７－１４２、２０００
  • 加藤順也　p27Kip1発現レベルを調節する新しい因子Jab1 細胞周期がわかる（中山敬一編集、羊土社）pp130-135, 2001
  • 加藤順也、友田紀一郎、荒田幸信、田中利明、加藤規子　 Cdkインヒビターp27の分解と癌　　 実験医学　１９：１７６－１８０、２００１
  • 田中利明、久保田真、安田國雄、加藤順也 トランスジェニックガエル作成法 遺伝子医学別冊　図で観る発生・再生医学実験マニュアルpp52-65, 2002
  • 加藤順也、友田紀一郎、加藤規子 細胞周期と癌 遺伝子医学別冊・遺伝子医学の入門書 これだけは知っておきたい遺伝子医学の基礎知識pp59-63, 2003